dc.contributor.author
Yu, Miao
dc.contributor.author
Terhorst‐Molawi, Dorothea
dc.contributor.author
Altrichter, Sabine
dc.contributor.author
Hawro, Tomasz
dc.contributor.author
Chen, Yu‐Di
dc.contributor.author
Liu, Bo
dc.contributor.author
Song, Xiao‐ting
dc.contributor.author
Zhao, Zuo‐tao
dc.contributor.author
Maurer, Marcus
dc.date.accessioned
2022-12-07T13:02:42Z
dc.date.available
2022-12-07T13:02:42Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37208
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36920
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
chronic urticaria
en
dc.subject
Duration of therapy
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Omalizumab in chronic inducible urticaria: A real‐life study of efficacy, safety, predictors of treatment outcome and time to response
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/cea.13838
dcterms.bibliographicCitation.journaltitle
Clinical & Experimental Allergy
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
730
dcterms.bibliographicCitation.pageend
734
dcterms.bibliographicCitation.volume
51
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33522024
dcterms.isPartOf.issn
0954-7894
dcterms.isPartOf.eissn
1365-2222
